Press Releases

May 26, 2026

Derek Hwang

Press Releases

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics has secured up to $150 million in non-dilutive financing from K2 HealthVentures, including an initial $50 million tranche, extending its cash runway into 2028. The funding supports advancement of its lead cell therapy candidate Descartes-08 through multiple clinical programs targeting autoimmune diseases such as myasthenia gr…

RNAC

May 26, 2026

Leila Farooq

Press Releases

Appian Corporation to Present in Upcoming Investor Conferences

Appian Corporation announced that CFO Serge Tanjga will present at the TD Cowen Technology, Media & Telecom Conference and the William Blair Growth Stock Conference in late May and early June 2026. Both presentations will be webcast live and later available for replay. The company specializes in process automation technology for large enterprises a…

APPN

May 26, 2026

Nina Shah

Press Releases

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer

Olema Pharmaceuticals announced a clinical trial collaboration with Bayer to evaluate the investigational KAT6 inhibitor OP-3136 in combination with Bayer's darolutamide in metastatic castration-resistant prostate cancer. The Phase 1b/2 study will enroll approximately 36 patients and aims to assess safety, tolerability, and preliminary anti-tumor a…

OLMA

May 26, 2026

Avery Klein

Press Releases

REalloys Reports Progress on Commercial Agreements with the Saskatchewan Research Council; Exclusive Heavy Rare Earth Supply Chain on Track Ahead of 2027 Statutory Deadline

REalloys Inc. announced significant progress on its commercial agreements with the Saskatchewan Research Council (SRC) to upgrade and expand SRC's rare earth processing facility. The company committed $20.6 million toward facility upgrades to increase production capacity of key rare earth metals such as Neodymium-Praseodymium, Dysprosium, and Terbi…

ALOY

May 26, 2026

Sofia Navarro

Press Releases

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics announced that the U.S. FDA has granted their appeal following the Formal Dispute Resolution process regarding their Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for treating neovascular age-related macular degeneration (nAMD). The FDA recognizes substantial evidence of effectiveness from clinical tri…

OTLK

May 26, 2026

Nina Shah

Press Releases

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting

Tonix Pharmaceuticals disclosed results from a comprehensive retrospective U.S. real-world claims analysis involving over 261,000 fibromyalgia patients, emphasizing the high comorbidity burden and extensive healthcare resource utilization associated with the condition. The company recently commercialized TONMYA®, a novel non-opioid analgesic approv…

TNXP

May 26, 2026

Derek Hwang

Press Releases

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy

Jade Biosciences announced the dosing of the first participant in its Phase 2 JUNIPER clinical trial evaluating JADE101, a monoclonal antibody targeting APRIL, in patients with immunoglobulin A nephropathy (IgAN). JADE101 aims to reduce pathogenic IgA production, offering a potentially effective and convenient treatment for this chronic autoimmune …

JBIO

May 26, 2026

Derek Hwang

Press Releases

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

Corbus Pharmaceuticals announced updated positive clinical results from its Phase 1/2 trial of CRB-701 (SYS6002), a next-generation Nectin-4 targeted antibody drug conjugate, showing robust efficacy in second-line oropharyngeal squamous cell carcinoma and cervical cancer. The treatment demonstrated confirmed objective response rates of 42.9% in OPS…

CRBP

May 26, 2026

Caleb Monroe

Press Releases

Spectral AI Receives FDA De Novo Clearance for DeepView® System for Burn Indication

Spectral AI, Inc. announced that the U.S. FDA granted De Novo Classification for its DeepView System, a non-invasive AI-powered diagnostic device designed to assess burn wound healing potential. This clearance authorizes the company to start commercial distribution of the device in the United States, marking a significant milestone for Spectral AI …

MDAI

May 26, 2026

Caleb Monroe

Press Releases

Holley Performance Brands Announces Share Repurchase Program of Up to $25 Million

Holley Performance Brands announced a Board-approved share repurchase program authorizing up to $25 million to buy back outstanding common stock. This move follows significant operational improvements including $100 million debt reduction, expanded margins, and portfolio realignment toward higher-growth brands. The program complements Holley's stra…

HLLY

May 26, 2026

Maya Rios

Press Releases

Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

Axsome Therapeutics announced presentations of new clinical data for AUVELITY, its treatment for major depressive disorder, at the American Society of Clinical Psychopharmacology 2026 Annual Meeting. The data focus on efficacy in patients with anxious distress and real-world clinical outcomes, demonstrating the drug's potential benefits and expandi…

AXSM

May 26, 2026

Priya Menon

Press Releases

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

Climb Bio, a clinical-stage biotech company, announced it will present new clinical data for its immunotherapy candidates CLYM116 and budoprutug at the European Renal Association Congress 2026. CLYM116 targets APRIL to treat IgA nephropathy, with initial Phase 1 safety data to be shown, while budoprutug, an anti-CD19 antibody, is in Phase 2 trials …

CLYM

May 26, 2026

Sofia Navarro

Press Releases

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

Cullinan Therapeutics announced an in-person Immunology Day event to showcase promising initial and updated clinical data from over 30 patients in systemic lupus erythematosus and rheumatoid arthritis studies using CLN-978 and Velinotamig, both T cell engager therapies. The company highlighted progress in multi-dose cohorts and shared plans for adv…

CGEM

May 26, 2026

Ajmal Hussain

Press Releases

AutoZone 3rd Quarter Total Company Same Store Sales Increase 3.9%; Domestic Same Store Sales Increase 4.1%; EPS of $38.07

AutoZone, Inc. reported an 8.4% increase in net sales to $4.8 billion for the third quarter ended May 9, 2026. Total company same store sales increased 3.9% (constant currency), driven by a 4.1% domestic same store sales growth. Operating profit rose 6.6% to $923.8 million, with diluted EPS increasing to $38.07 compared to $35.36 last year. The com…

AZO

May 26, 2026

Leila Farooq

Press Releases

Stantec joint venture to deliver Greater Western Water’s infrastructure program

Stantec, in joint venture with Jacobs, has been selected by Greater Western Water to support a five-year infrastructure program for water and sewer systems across Melbourne’s rapidly growing western region. The program aims to deliver sustainable, resilient water services to accommodate population growth and climate challenges through advanced engi…

STN

May 26, 2026

Jordan Park

Press Releases

CSW Industrials Reports Robust Fiscal 2026 Fourth Quarter with Record Quarterly and Full Year Results; Contractor Solutions Segment Returns to Positive Organic Growth in Fourth Quarter

CSW Industrials announced record revenue and adjusted EBITDA for fiscal 2026, driven primarily by strategic acquisitions and solid organic growth in the Contractor Solutions and Specialized Reliability Solutions segments. Despite some reported EPS decline due to non-cash impairments and higher interest expenses, adjusted EPS increased by 6.9% year-…

CSW

May 26, 2026

Avery Klein

Press Releases

Aurora Mobile Limited Announces First Quarter 2026 Unaudited Financial Results

Aurora Mobile Limited (NASDAQ: JG) announced its unaudited Q1 2026 financial results, achieving RMB93.3 million (US$13.5 million) in revenue, a 5% year-over-year increase. The company reported its fourth consecutive GAAP net profit quarter with net income of RMB1.2 million (US$0.2 million), improved gross profit and margin, and strong SaaS metrics …

JG

May 26, 2026

Hana Yamamoto

Press Releases

Editas Medicine Announces Proposed Public Offering

Editas Medicine, a gene editing company listed on Nasdaq, announced the commencement of an underwritten public offering of its common stock and accompanying warrants. The offering is subject to market conditions and aims to raise capital to support its pipeline of CRISPR-based transformative medicines. Cantor and Wells Fargo Securities are managing…

EDIT

May 26, 2026

Marcus Reed

Press Releases

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

Kura Oncology announced encouraging first-in-human data from its FIT-001 trial evaluating darlifarnib plus adagrasib in heavily pretreated patients with KRAS G12C-mutated advanced solid tumors, including pancreatic, lung, and colorectal cancers. Tumor shrinkage was observed in 77% of evaluable patients with objective response rates of 67% in pancre…

KURA

May 26, 2026

Ajmal Hussain

Press Releases

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine announced positive preclinical data demonstrating that a single dose of its gene-editing candidate, EDIT-401, achieved approximately 90% reductions in LDL cholesterol, Lp(a), and ApoB in non-human primates. These findings support EDIT-401 as a potentially best-in-class in vivo gene editing therapy for hyperlipidemia and cardiovascul…

EDIT

May 26, 2026

Priya Menon

Press Releases

BGIN BLOCKCHAIN LIMITED Launches ASIC Chip Customization Solutions Business and Completes Inaugural Customer Delivery

BGIN Blockchain Limited announced the launch of its ASIC Chip Customization Solutions business, leveraging its expertise in ASIC chip design and mining hardware engineering to serve third-party customers. The company completed its inaugural delivery of 3,000 customized mining machines to a Proof-of-Work protocol project, marking its entry into offe…

BGIN

May 26, 2026

Caleb Monroe

Press Releases

Auddia Reports Strong Artist and Industry Response to Discovr Radio’s Toronto Debut at Departure Festival + Conference, Identifies City as Key Growth Hub

Auddia Inc. reported a highly successful debut of its AI-driven artist discovery platform, Discovr Radio, at the Departure Festival + Conference in Toronto. The event drew over 65 demo submissions and significant attendance, demonstrating strong demand for AI-powered, data-driven music promotion in the Canadian market. Toronto is identified as a st…

AUUD

May 26, 2026

Leila Farooq

Press Releases

New TransUnion Study Challenges Credit Myths About Canadian Gig Workers

TransUnion's new study challenges credit myths about Canadian gig workers, highlighting their responsible credit behavior and significant role in household income. The report shows gig workers have credit profiles similar to the general population but face obstacles in credit applications, underscoring a need for lenders to adapt credit assessment …

TU

May 26, 2026

Sofia Navarro

Press Releases

Emira 420 Sport: the lightest and most powerful Emira yet

Lotus Technology Inc. announced the launch of the Emira 420 Sport, the most powerful and lightest version of the Emira sports car to date. Featuring a 2.0-litre turbocharged engine with 420PS, advanced lightweight materials, enhanced aerodynamics, and improved handling, the new model aims to deliver superior performance both on road and track. The …

LOT

May 26, 2026

Derek Hwang

Press Releases

Lithia & Driveway (LAD) Announces Share Repurchase Authorization Increase

Lithia & Driveway (NYSE: LAD) announced an increase in its share repurchase authorization by $500 million, raising the remaining buyback capacity to $726 million. The company has repurchased a significant portion of its outstanding shares year-to-date, emphasizing its strong cash flows and commitment to maximizing shareholder returns. This move und…

LAD